Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Clinical Trial Summary

The study objective is to determine whether use of Rhopressa improves the ability of corneal endothelial cells to maintain appropriate corneal hydration in patients with Fuchs endothelial corneal dystrophy (FECD), which could help delay or prevent the need for a corneal transplant.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03813056` - Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy	Phase 2
Recruiting	`NCT02423213` - DISCOVER Study: Microscope-integrated Intraoperative OCT Study
Completed	`NCT00624221` - Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty	N/A
Completed	`NCT02423161` - PIONEER: Intraoperative and Perioperative OCT Study	N/A

See also

Status

Clinical Trial

Phase

Recruiting

NCT03813056 - Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy

Phase 2

Recruiting

NCT02423213 - DISCOVER Study: Microscope-integrated Intraoperative OCT Study

Completed

NCT00624221 - Study of Eye Bank Pre-cut Donor Grafts for Endothelial Keratoplasty

N/A

Completed

NCT02423161 - PIONEER: Intraoperative and Perioperative OCT Study

N/A

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT04051463
Study type	Interventional
Source	Price Vision Group
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	August 5, 2019
Completion date	July 1, 2020

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms